Market
Which pharmaceutical company will first begin human trials for ErSO-TFPy by the end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Announcements from pharmaceutical companies or clinical trial registries
Story
New Ultra-Fast Cancer Treatment ErSO-TFPy Promises Less Side Effects and Rapid Results in Less Than a Second
Jan 23, 2025, 03:02 AM
Recent research highlights a groundbreaking ultra-fast cancer treatment that could potentially replace conventional radiotherapy. This innovative approach, referred to as Flash Radiotherapy, promises to address a broader range of cancers while minimizing side effects and significantly reducing treatment time to less than a second. Additionally, a study on the drug candidate ErSO-TFPy has demonstrated its effectiveness in eradicating small breast cancer tumors in mice, indicating potential for treating estrogen receptor-positive breast cancer with minimal side effects. Further testing is required to confirm these findings and assess the treatments' applicability in clinical settings.
View original story
Similar markets
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
Pfizer • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Eli Lilly • 25%
Drug B • 25%
Drug A • 25%
None • 25%
Drug C • 25%
No • 50%
Yes • 50%
Other • 25%
Roche • 25%
Pfizer • 25%
Eli Lilly • 25%
Yes • 50%
No • 50%
United States • 25%
Other • 25%
Japan • 25%
Germany • 25%
GlaxoSmithKline • 25%
Other • 25%
AstraZeneca • 25%
Pfizer • 25%